CTLA4 and colorectal carcinoma: Preliminary findings of immunotherapy efficacy in localized dMMR/MSI-H CRC cancer stem from post-hoc analyses of the phase-2 NICHE trial, where 2 cycles of nivolumab (anti-PD1) and 1 cycle of ipilimumab (anti-CTLA4) resulted in a 69% pathological complete response rate (pCR) among the 32 patients of the dMMR/MSI-H cohort assessed for response, with 100% patients free from disease recurrence after a median follow-up of 25 months.